Clinical Trial Update: Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating two doses of immediate-release retigabine (900 mg/day and 600 mg/day) as adjunctive therapy in adult Asian subjects with drug-resista…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• Retigabine Immediate Release (retigabine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 3 | Status: TERMINATED | Results posted: 2014-09-08